Mobile

A Phase III, randomized, double-blind, placebo-controlled multi-center study of ASA404 in combination with paclitaxel and carboplatin as first-line treatment for locally advanced or metastatic (stage ...

Mise à jour : Il y a 4 ans
Référence : EUCTR2007-006072-11

A Phase III, randomized, double-blind, placebo-controlled multi-center study of ASA404 in combination with paclitaxel and carboplatin as first-line treatment for locally advanced or metastatic (stage IIIb/IV) non-small cell lung cancer (NSCLC)

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective is to compare the overall survival (OS) of patients receiving ASA404 or placebo in combination with paclitaxel and carboplatin for first-line treatment of stage IIIb/IV NSCLC.

Critère d'inclusion

  • This phase III trials is conducted world-wide in order to demonstrate safety and efficacy of ASA404 in combination with a paclitaxel-carboplatin chemotherapy in the treatment of patients with stage IIIb/IV NSCLC who are eligible for a first line chemotherapy. The study population will consist of patients with NSCLC of all histologies eligible for first-line therapy

Liens